Video

Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence and Veterans Affairs (VA) hospital networks, marking a significant step forward in the Company’s U.S. commercial strategy.

Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on the Company’s commercial progress and global expansion strategy.

Surgeon adoption is a key factor in the commercialisation of medical technologies. But what influences whether a surgeon chooses to adopt a new product in clinical practice?

The AFR has profiled Orthocell’s increased investment in Marine Biomedical and its novel bone-repair technology, PearlBone™, in this article by Tom Rabe titled ‘The company repairing human bone with Kimberley pearl shells.’  Orthocell Chairman John Van Der Wielen explains that this investment contributes to Orthocell’s broader strategy to support surgeons with a more complete trauma-repair toolkit spanning nerve, tendon and bone, while bringing new […]

Orthocell has entered into a binding Formal Agreement with Marine Biomedical, increasing its equity interest from 1.72% to 11.7% for a total investment of AU$1.05 million.   As part of the transaction, Orthocell has secured a first right of refusal over global distribution rights for PearlBone™, Marine Biomedical’s bone regeneration technology, and any future bone repair and regeneration products.  PearlBone is an […]

During his visit to Australia last week for Orthocell’s annual nerve repair and reconstruction symposium, US reconstructive surgeon Dr Ian Valerio made the time to speak with Stockhead’s Tylah Tully about the significant global opportunity for Remplir, following recent FDA approval.